Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 23;15(10):e0241263.
doi: 10.1371/journal.pone.0241263. eCollection 2020.

Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis

Manuela Savino  1 , Anna Casula  1 , Shalini Santhakumaran  1 , David Pitcher  1 , Esther Wong  1 , Winnie Magadi  1 , Katharine M Evans  1 , Fran Benoy-Deeney  1 , James Griffin  1 , Lucy Plumb  1   2 , Retha Steenkamp  1 , Dorothea Nitsch  1   3   4 , James Medcalf  1   5   6
Affiliations

Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis

Manuela Savino et al. PLoS One. .

Abstract

Kidney disease is a recognised risk factor for poor COVID-19 outcomes. Up to 30 June 2020, the UK Renal Registry (UKRR) collected data for 2,385 in-centre haemodialysis (ICHD) patients with COVID-19 in England and Wales. Overall unadjusted survival at 1 week after date of positive COVID-19 test was 87.5% (95% CI 86.1-88.8%); mortality increased with age, treatment vintage and there was borderline evidence of Asian ethnicity (HR 1.16, 95% CI 0.94-1.44) being associated with higher mortality. Compared to the general population, the relative risk of mortality for ICHD patients with COVID-19 was 45.4 and highest in younger adults. This retrospective cohort study based on UKRR data supports efforts to protect this vulnerable patient group.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Kaplan Meier unadjusted survival for Sars-CoV-2 positive patients—2-week survival.
See this image and copyright information in PMC

References

    1. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic comparison of two animal to human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020; 12(2): 244. - PMC - PubMed
    1. Wu Z, McGoogan J. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID 2019) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Centre for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242. 10.1001/jama.2020.2648 - DOI - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054 10.1016/S0140-6736(20)30566-3 - DOI - PMC - PubMed
    1. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J. Med. Virol. March 2020. 10.1002/jmv.25757 - DOI - PMC - PubMed
    1. Ludvigsson JF. Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. Mar 2020. 10.1111/apa.15270 - DOI - PMC - PubMed

MeSH terms